Baker, Donelson, Bearman, Caldwell & Berkowitz PC
04/24/2026 | Press release | Distributed by Public on 04/24/2026 09:56
Baker Donelson Represents Cumberland Pharmaceuticals in Strategic Transaction to Integrate Commercial Business with Apotex
The national law firm of Baker Donelson served as legal counsel to Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, in an agreement with an affiliate of Apotex Inc., the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses.
Under the terms of the agreement, Apotex will acquire Cumberland's line of branded pharmaceuticals for cash consideration of $100 million, and create a platform to deliver specialty medicines that improve the quality of patient care. The transaction is subject to authorization and approval by Cumberland's shareholders.
The Baker Donelson team advising Cumberland Pharmaceuticals on this transaction was led by Tonya Mitchem Grindon, chair of the Firm's Business Department and shareholder in the Nashville office. Other members of the team included shareholders Nathan Kibler (Knoxville) and Charles W. "Chuck" Goldberg Jr. (Nashville); and Nashville associates Aaron S. Chaloner Ph.D., Tyler Dove, Paulluvi Henley, and Jack Ritossa.
Cumberland will retain its pipeline product candidates, which it intends to focus on developing following the closing of the transaction. It will also retain its majority ownership position in Cumberland Emerging Technologies Inc.
Apotex was represented by the firm of Kirkland & Ellis.
See the Cumberland Pharmaceuticals press release here.
Baker, Donelson, Bearman, Caldwell & Berkowitz PC published this content on April 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2026 at 15:56 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]